Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kintor Pharmaceutical Limited has successfully enrolled the first participant in its pivotal clinical trial for KX-826 tincture, aimed at treating male androgenetic alopecia in China. This step marks significant progress in a study designed to assess the efficacy and safety of their innovative treatment. Additionally, their long-term safety trial has shown promising results, indicating excellent safety and tolerability of the drug.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.